The Indian Pharmaceutical Market (IPM) clocked Rs 5902 crores in February 2014. It has grown at 4.5 per cent in the month. Amongst the top 10, Sun Pharma grew at 18.1 per cent followed by Lupin at 9.3 per cent and Alkem at 6.7 per cent. 29 corporates have crossed the growth of IPM amongst top 50.
Amongst the top 50 corporates, Biocon has registered the highest growth of 46.7 per cent followed by Ajanta at 42.5 per cent and Eris at 34.9 per cent. Amongst the 11-20 ranked companies, Aristo showed a growth of 22.4 per cent followed by Torrent at 16.6 per cent and Glenmark at 16.3 per cent.
|
With Bonus Units at Full Value (Val in Crs)
|
||||||||
|
Val in Crs
|
Rank
|
MAT Feb -14
|
Feb-14
|
|||||
|
CORPORATE
|
MAT
|
MTH
|
Val (Cr)
|
MS%
|
GR%
|
Val (Cr)
|
MS%
|
GR%
|
| IPM |
75149
|
100.00
|
5.9
|
5902
|
100.00
|
4.5
|
||
| Abbott + Abbott HC + Novo |
1
|
1
|
4857
|
6.46
|
5.1
|
385
|
6.52
|
3.4
|
| Sun Pharma |
2
|
2
|
4035
|
5.37
|
17.3
|
333
|
5.65
|
18.1
|
| Cipla |
3
|
3
|
3743
|
4.98
|
5.3
|
306
|
5.19
|
0.6
|
| Zydus + Biochem |
4
|
4
|
3334
|
4.44
|
9.9
|
269
|
4.56
|
1.1
|
| Ranbaxy |
5
|
5
|
2886
|
3.84
|
-0.4
|
218
|
3.70
|
-3.1
|
| Glaxo |
6
|
6
|
2771
|
3.69
|
-15.0
|
207
|
3.51
|
-17.5
|
| Mankind |
7
|
7
|
2675
|
3.56
|
5.3
|
207
|
3.50
|
4.0
|
| Alkem + Cachet + Indchemie |
8
|
9
|
2624
|
3.49
|
10.8
|
195
|
3.30
|
6.7
|
| Lupin |
9
|
8
|
2514
|
3.35
|
12.6
|
204
|
3.46
|
9.3
|
| Pfizer + Wyeth |
10
|
10
|
2198
|
2.92
|
3.3
|
173
|
2.92
|
0.0
|
| Emcure + Zuventus |
11
|
11
|
2112
|
2.81
|
15.3
|
167
|
2.82
|
7.7
|
| Macleods |
12
|
12
|
1954
|
2.60
|
8.4
|
163
|
2.76
|
15.0
|
| Sanofi-Aventis + Universal |
13
|
15
|
1924
|
2.56
|
2.0
|
142
|
2.40
|
-3.7
|
| Intas |
14
|
13
|
1885
|
2.51
|
9.0
|
152
|
2.58
|
-1.1
|
| Aristo |
15
|
14
|
1813
|
2.41
|
11.6
|
143
|
2.42
|
22.4
|
| Glenmark |
16
|
16
|
1619
|
2.15
|
16.3
|
133
|
2.25
|
16.3
|
Sun Pharma has become the second corporate to enter the Rs 4000-crore club. Meyer Organics has also entered the Rs 350-crore club.
Indian companies have grown at 6.9 per cent versus -1.7 per cent for MNCs in February 2014. Amongst the top 50 in MNCs, MSD grew the highest at 17.3 per cent, followed by AstraZeneca at 15.3 per cent and Merck at 5.1 per cent. The DPCO 2013 containing molecules market was at –13.6 per cent whereas the non-DPCO market grew by 7.4 per cent resulting in an overall growth of 4.5 per cent. The DPCO 2013 portfolio for GSK de-grew at 30.7 per cent and Ranbaxy de-grew by 25.2 per cent, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio degrowing at 6.8 per cent. From the therapy perspective, 11 therapies have outgrown the IPM growth and four therapies have double digit growths. The respiratory market grew at 6.2 per cent, gastrointestinal market grew at 5.1 per cent whereas the anti-infectives degrew at 0.9 per cent. In the chronic business segment, anti-diabetic market grew at 13.3 per cent while the cardiac marketgrew at 5.9 per cent. The derma market grew by 12.5 per cent.
|
Val in Crs
|
MAT Feb 14
|
Month Feb -14
|
||
|
Super Group
|
Val in Crs
|
Gr%
|
Val in Crs
|
Gr%
|
| IPM |
75149
|
5.9
|
5902
|
4.5
|
| ANTI-INFECTIVES |
12591
|
0.7
|
945
|
-0.9
|
| CARDIAC |
9291
|
8.3
|
752
|
5.9
|
| GASTRO INTESTINAL |
8467
|
5.7
|
640
|
5.1
|
| VITAMINS / MINERALS / NUTRIENTS |
6717
|
4.8
|
511
|
4.0
|
| RESPIRATORY |
5911
|
9.3
|
518
|
6.2
|
| PAIN / ANALGESICS |
5417
|
3.7
|
412
|
2.3
|
| ANTI DIABETIC |
5260
|
14.6
|
434
|
13.3
|
| NEURO / CNS |
4703
|
7.8
|
375
|
4.3
|
| GYNAECOLOGICAL |
4661
|
1.2
|
361
|
-4.0
|
| DERMA |
4159
|
10.6
|
334
|
12.5
|
| OPHTHAL / OTOLOGICALS |
1360
|
8.6
|
105
|
6.8
|
| HORMONES |
1281
|
5.9
|
102
|
1.9
|
| VACCINES |
1115
|
-2.4
|
75
|
-19.3
|
| ANTI-NEOPLASTICS |
1009
|
24.9
|
91
|
45.8
|
| OTHERS |
923
|
5.5
|
82
|
23.1
|
| BLOOD RELATED |
898
|
3.1
|
67
|
-0.1
|
| ANTI MALARIALS |
621
|
1.0
|
35
|
9.4
|
| SEX STIMULANTS / REJUVENATORS |
428
|
5.4
|
36
|
4.6
|
| STOMATOLOGICALS |
336
|
7.5
|
27
|
8.7
|
From a regional perspective, 10 regions have outgrown the IPM growth. Jharkhand market grew the highest at 14 per cent followed by Vidarbha market at 13.2 per cent. Three regions had negative growths. The biggest molecule, Amoxycillin + Clavulanic degrew by 4.4 per cent, whereas Cefixime degrew at 5.7 per cent. The markets of Glimepiride + Metformin grew at 33 per cent, protein supplement by 25.1 per cent, Vitamin D grew by 27.8 per cent, Rosuvastain by 18.9 per cent, Telmisartan by 17.6 per cent and Levocetirizine + Montelukast by 15.9 per cent.
Glycomet-GP and Monocef have registered 23 per cent growth amongst the top 10 brands. Amongst the top brands in the IPM, Lantus grew by 25 per cent, Skinlite by 19 per cent, Aciloc by 15 per cent amongst top 25 brands. A total of 107 brands were launched in February 2014. Buscogast and Ferinject are the top NIs.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharma market research company formed by All Indian Origin Chemists & Distributors (AIOCD) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net